Axiogenesis Cor.At mESC cardiomyocytes
Posted: 21 June 2010  |  Supplied by: Lonza Australia Pty Ltd

Axiogenesis Cor.At mESC cardiomyocytes

Online: www.lonza.com
Phone: 03 9550 0883

Embryonic stem cell-derived cardiomyocytes have many of the phenotypic properties of primary cardiomyocytes and show great potential to model human diseases. The Cor.At cells are cardiomyocytes derived from transgenic mouse embryonic stem cells and are available cryopreserved in ampoules.

The cells are highly pure with ampoules containing 99% cardiomyocytes. Their minimal lot-to-lot variation is claimed to give consistent performance and the standardised production process ensures stable supply.

The cardiomyocytes are a good predictive model with relevant background including all important ion channels well characterised.

They are suitable for applications including: electrophysiology (patch clamp, microelectrode arrays, Ca2+ flux analysis), non-arrhythmic cardiotoxicity (cell viability, label-free analysis, troponin release), drug profiling and target discovery (hypertrophy, gene expression, transfection, tissue engineering).


Have you seen our digital edition?

Mag_promo_cover YOUR industry magazine is now available as a digital download.

FREE to qualified readers

No downloads required

Easy-to-use share function

Click here to subscribe now >

WFonline: Vital and informative media